{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-004247","form_type":"8-K","ticker":null,"cik":"0001173281","company_name":"NeuBase Therapeutics, Inc.","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.556518+00:00","generated_at":"2026-06-06T22:26:51.275927+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuBase terminates CEO Dietrich Stephan; appoints CFO Todd Branning as interim CEO","bullets":["Board terminated Dietrich A. Stephan as CEO without cause, effective Jan 16, 2024.","Todd P. Branning, CFO since Jan 2022, appointed interim CEO, retaining CFO role.","Dr. Stephan expected to continue serving on the Board.","Branning's compensation unchanged as a result of the appointment.","No family relationships or material transactions with Branning disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-004247","json":"https://secwatch.observer/filing/0001104659-24-004247.json","markdown":"https://secwatch.observer/filing/0001104659-24-004247.md","text":"https://secwatch.observer/filing/0001104659-24-004247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/tm243413d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:26:51.275927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"348ab35d8b","claim":"Todd P. Branning was appointed as interim Chief Executive Officer at NeuBase Therapeutics, Inc..","evidence_excerpt":"appointed Todd P. Branning, who has served as the Company’s Chief Financial Officer since January 2022, as the Company’s interim Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f993ea4d7f","claim":"Dietrich A. Stephan was terminated as Chief Executive Officer at NeuBase Therapeutics, Inc..","evidence_excerpt":"terminated the employment of Dietrich A. Stephan, Ph.D. as Chief Executive Officer of the Company, without cause","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465924004247/0001104659-24-004247-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}